Benitec Biopharma (BNTC) Cash from Financing Activities (2019 - 2025)

Benitec Biopharma has reported Cash from Financing Activities for 6 years, with the latest figure at $98.2 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 449.69% year-over-year to $98.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.2 million (up 62.3% YoY) and the FY2025 annual result came in at $70.5 million, up 3.61% from the prior year.
• Cash from Financing Activities grew to $98.2 million in Q4 2025 per BNTC's latest filing, from $2.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $98.2 million in Q4 2025 and troughed at $3000.0 in Q1 2021.
• A 5-year average of $24.1 million and a median of $17.9 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 45720.51% in 2024, then plunged 93.65% in 2025.
• Over 5 years, Cash from Financing Activities stood at $12.7 million in 2021, then gained by 26.42% to $16.0 million in 2022, then slumped by 99.76% to $39000.0 in 2023, then jumped by 45720.51% to $17.9 million in 2024, then jumped by 449.69% to $98.2 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $98.2 million, $2.5 million, and $28.4 million for Q4 2025, Q2 2025, and Q1 2025 respectively.